

## FORM 9

### **NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

**(or securities convertible or exchangeable into listed securities<sup>1</sup>)**

Name of Listed Issuer:

Symbol(s):

**CORE ONE LABS INC.** (the "Issuer").

COOL

Date: May 5, 2021 Is this an updating or amending Notice: Yes ☐ No ☒

If yes provide date(s) of prior Notices: N/A.

Issued and Outstanding Securities of Issuer Prior to Issuance: 109,453,408

#### **Pricing**

Date of news release announcing proposed issuance: May 4, 2021 or

Date of confidential request for price protection: \_\_\_\_\_

Closing Market Price on Day Preceding the news release: \$0.81 or

Day preceding request for price protection: \_\_\_\_\_

#### **Closing**

Number of securities to be issued: 3,870,000

Issued and outstanding securities following issuance: 113,323,408

#### **Instructions:**

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to [listings@thecse.com](mailto:listings@thecse.com) with an appendix that includes the information in Table 1B for ALL placees.

**Part 1. Private Placement**

**Table 1A – Summary**

**Not applicable**

**Table 1B – Related Persons**

**Not applicable**

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date <sup>(1)</sup>	Describe relationships to Issuer <sup>(2)</sup>

<sup>1</sup>An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: **Not applicable**
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. **Not applicable**\_\_\_\_\_.
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: **Not applicable**\_\_\_\_\_  
\_\_\_\_\_.
4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.
5. Description of securities to be issued: **Not applicable**
  - (a) Class Common shares .
  - (b) Number \_\_\_\_\_.
  - (c) Price per security \_\_\_\_\_.
  - (d) Voting rights \_\_\_\_\_.

6. Provide the following information if warrants, (options) or other convertible securities are to be issued: **Not applicable**
- (a) Number \_\_\_\_\_ .
- (b) Number of securities eligible to be purchased on exercise of warrants (or options) \_\_\_\_\_ .  
\_\_\_\_\_ .
- (c) Exercise price \_\_\_\_\_ .
- (d) Expiry date \_\_\_\_\_ .
7. Provide the following information if debt securities are to be issued: **Not applicable**
- (a) Aggregate principal amount \_\_\_\_\_ .
- (b) Maturity date \_\_\_\_\_ .
- (c) Interest rate \_\_\_\_\_ .
- (d) Conversion terms \_\_\_\_\_ .
- (e) Default provisions \_\_\_\_\_ .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):  
  
**Not applicable.**
- (b) Cash **Not applicable**
- (c) Securities **Not applicable**
- (d) Other **Not applicable** \_\_\_\_\_ .
- (e) Expiry date of any options, warrants etc. **Not applicable** \_\_\_\_\_ .
- (f) Exercise price of any options, warrants etc. **Not applicable** \_\_\_\_\_ .

9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship **Not applicable**.
- 
10. Describe any unusual particulars of the transaction (i.e. tax “flow through” shares, etc.). **Not applicable**
- 
11. State whether the private placement will result in a change of control.
- Not applicable**\_\_\_\_\_
12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. \_\_\_\_\_
- 
13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

## **Part 2. Acquisition**

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material:

**On May 4, 2021, the Issuer completed its acquisition of Akome Biotech Ltd. (“Akome”), a Canadian company that holds proprietary cGMP drug formulations which are comprised of psychedelic compounds and plant bioactives. Through data mapping, Akome has identified that the various psychedelic compounds catalyze with the introduction of the plant bioactives and improve the efficacy of the psychoactive molecules within the psychedelic compounds. Akome currently has four (4) provisional matter of composition patents filed with the United States Patent and Trademark Office for these plant bioactive-psychedelic drug formulations, all of which target different neurological disorders: 2 DMT-**

based, for the addressing Parkinson's Disease, and Ischemic Stroke, respectively; one (1) psilocybin-based, for addressing Alzheimer's Disease; and one (1) ketamine-based, for addressing depression.

With this strategic acquisition, the scope of the Issuer's psychedelics' bio-pharma research and development division will broaden to include drug formulations that effectively target and change underlying processes at the root of neurological disorders, and/or prevent further neurological damage that result from the disorders.

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material:

On April 28, 2021, the Issuer announced that it entered into a definitive purchase agreement (the "Agreement") with Akome and on May 4, 2021 the Issuer announced that it satisfied all conditions precedent to completing the Transaction (as defined below). In consideration for the acquisition of all of the outstanding share capital of Akome (the "Transaction"), the Issuer issued a total of 3,500,000 common shares in the capital of the Issuer (the "Consideration Shares") at a deemed price of CAD\$0.91 per share.

The Issuer is at arms-length from Akome and the Transaction does not constitute a fundamental change for the Issuer, nor does it result in a change of control of the Issuer, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with the Transaction, the Issuer paid administration fees of 35,000 shares to each of two parties that provided administrative support in connection with the Transaction and finder's fees of 100,000 common shares of the Issuer to each of three third-party consultants who introduced the parties and assisted with the Transaction. These fee shares are subject to a four month hold in accordance with the policies of the Canadian Securities Exchange.

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:

(a) Total aggregate consideration in Canadian dollars: **\$3,185,000.00 payable in common shares of the Issuer at a deemed price of CAD\$0.91 per share .**

(b) Cash: **None** .

(c) Securities (including options, warrants etc.) and dollar value:

**3,500,000 common shares at a deemed value of CAD\$0.91 per share.**

(d) Other: **None.**

(e) Expiry date of options, warrants, etc. if any **Not applicable.**

(f) Exercise price of options, warrants, etc. if any: **Not applicable** .

(g) Work commitments: **Not applicable.**

4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).

**The purchase price was determined via arm's length negotiations between the parties.**

5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer:

**Not applicable.**

6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date(1)	Describe relations -hip to Issuer (2)
Santiago Ferro	500,000	\$0.91	N/A	Section 2.16 of NI 45-106	Nil	N/A	None
Jen Gretchen	100,000	\$0.91	N/A	Section 2.16 of NI 45-106	Nil	N/A	Related Party
Burton Financial Inc.	1,500,000	\$0.91	N/A	Section 2.16 of NI 45-106	Nil	N/A	None
Fadia Saad	1,400,000	\$0.91	N/A	Section 2.16 of NI 45-106	Nil	N/A	None

**FORM 9 – NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES**

(2) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired:

**Due diligence, including the examination of all financial records, obligations, contracts and agreements was undertaken by management of the Issuer.**

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):

- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, and if a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer):

**As noted below, a total of 370,000 common shares of the Issuer have been issued to five (5) arm's length parties in connection with the Transaction.**

- (b) Cash **Not applicable** .

- (c) Securities

**370,000 common shares of the Issuer as noted below:**

Recipient	Type of Fee	No. of Shares
Keysun Group	Finder's Fee	100,000
Ascent Marketing Ltd.	Finder's Fee	100,000
David Schmidt	Finder's Fee	100,000
Winchester Advisory Corp.	Administrative Success Fee	35,000
Fiore Management & Advisory Corp.	Administrative Success Fee	35,000
<b>Total</b>		<b>370,000</b>

- (d) Other **Not applicable** .
- (e) Expiry date of any options, warrants etc. **Not applicable**
- (f) Exercise price of any options, warrants etc. **Not applicable** .

9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with the Issuer and provide details of the relationship. **Not applicable**
10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. **Not applicable**
- .



## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
  - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
  - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated May 5, 2021.

Joel Shacker  
Name of Director or Senior  
Officer

s/ "Joel Shacker"  
Signature

Chief Executive Officer  
Official Capacity

## **Appendix A**

### **PERSONAL INFORMATION COLLECTION POLICY REGARDING FORM 9**

The Canadian Securities Exchange and its subsidiaries, affiliates, regulators and agents (collectively, “CSE or the “Exchange”) collect and use the information (which may include personal or other information) which has been provided in Form 9 for the following purposes:

- 
- To determine whether an individual is suitable to be associated with a Listed Issuer;
- To determine whether an issuer is suitable for listing;
- To determine whether allowing an issuer to be listed or allowing an individual to be associated with a Listed Issuer could give rise to investor protection concerns or could bring the Exchange into disrepute;
- To conduct enforcement proceedings;
- To ensure compliance with Exchange Requirements and applicable securities legislation; and
- To fulfil the Exchange’s obligation to regulate its marketplace.

The CSE also collects information, including personal information, from other sources, including but not limited to securities regulatory authorities, law enforcement and self-regulatory authorities, regulation service providers and their subsidiaries, affiliates, regulators and agents. The Exchange may disclose personal information to these entities or otherwise as provided by law and they may use it for their own investigations.

The Exchange may use third parties to process information or provide other administrative services. Any third party will be obliged to adhere to the security and confidentiality provisions set out in this policy.

All personal information provided to or collected by or on behalf of The Exchange and that is retained by The Exchange is kept in a secure environment. Only those employees who need to know the information for the purposes listed above are permitted access to the information or any summary thereof. Employees are instructed to keep the information confidential at all times.

Information about you that is retained by the Exchange and that you have identified as inaccurate or obsolete will be corrected or removed.

If you wish to consult your file or have any questions about this policy or our practices, please write the Chief Privacy Officer, Canadian Securities Exchange, 220 Bay Street – 9th Floor, Toronto, ON, M5J 2W4.